Bayer Collaborates with PAPACKS to Co-create Alternative-to-Plastic Packaging for Consumer Health Products
7.6.2024 09:16:37 CEST | news aktuell GmbH | Press release
This relationship aims to advance Bayer’s commitment to ensure 100% of product packaging is recycle-ready or reusable by 2030.

(Basel, Switzerland, June 6, 2024) – Bayer has launched a strategic collaboration with PAPACKS to develop fiber-based packaging, as an alternative to using traditional plastic packaging for some of the company’s Consumer Health products, which include brands like Aspirin, Bepanthen and Claritin. This is a step forward in Bayer’s commitment to ensure 100% of the packaging used in their self-care products contribute to the circular economy and are recycle-ready or reusable by 2030.
The collaboration aims to develop biodegradable, pulp-based packaging made from responsible virgin fibers, featuring PAPACK’s moulded pulp technology that uses materials derived from renewable sources and a plant-based coating.
“Reducing plastic utilization is one of the greatest challenges of our industry, so we’re proud to join forces with PAPACKS to accelerate progress towards using eco-friendly, renewable sources for our packaging,” said Jesse DelGigante, Director, Global Packaging Innovation for Bayer’s Consumer Health division. “This collaboration is a strong step forward in our sustainable packaging journey.”
“We’re looking forward to the challenge of combining our unique pulp technology with plant-based coating with the rigorous standards mandated by regulatory agencies for over-the-counter medicines,” said Tahsin Dag, Founder & CEO of Papacks. “We expect this collaboration to help redefine packaging standards for the industry.”
As a part of Bayer’s commitment to advance sustainable packaging solutions, this collaboration with PAPACKS follows the recent announcement that the company has joined the Blister Pack Collective to reduce single-use plastics in healthcare packaging.
About PAPACKS
PAPACKS is a leading producer of moulded pulp packaging solutions, specializing in eco-friendly alternatives to traditional plastic packaging. Committed to sustainability and innovation, PAPACKS develops cutting-edge solutions, utilizing biodegradable materials derived from renewable sources and featuring a plant-based coating, with a focus on environmental responsibility. For more information, go to www.papacks.com
About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2023, the Group employed around 100,000 people and had sales of 47.6 billion euros. R&D expenses before special items amounted to 5.8 billion euros. For more information, go to www.bayer.com.
Contacts
Manuel LeibrockCMOPAPACKS®
presse@papacks.comImages

About news aktuell GmbH
news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Webasto Air Top Pro 25: a new, exceptionally quiet parking heater for campers22.10.2026 13:52:44 CEST | Press release
Why should the camping season end just because summer is over? The colder months offer unique experiences—from skiing and snowshoeing to simply enjoying the winter landscape. To ensure your motorhome or campervan remains a comfortable retreat even in low temperatures, the right heating solution is crucial.
Polarise Launches Sovereign AI Cloud at NVIDIA GTC Berlin, Delivering Enterprise AI From Data Center to Application22.10.2026 10:00:00 CEST | Press release
With Polarise Rise and Polarise Drive, the German AI provider extends its own European AI Factories into a full-stack sovereign cloud
Democracy News Alliance: Fiscal strength doesn't guarantee public goods delivery, US study finds21.10.2026 09:55:20 CEST | Press release
New York/DNA - A newly released study of US state government performance found strong partisan and regional patterns within three pillars of governance: democratic accountability, state capacity and public goods provision. Yet, the US states’ outcomes differ in important ways from international comparisons, as the three governance dimensions show limited correlation, the researchers found.
agineo expands partnership with ServiceNow, launches AI Control Tower as a Service20.10.2026 13:06:01 CEST | Press release
New managed service provides transparency into the AI landscape and helps companies centrally manage AI, monitor risks and regulatory requirements, and highlight business benefits.
Grünenthal advances proprietary Nociceptin Receptor (NOP) Agonist into Phase II trial in acute pain20.10.2026 10:17:49 CEST | Press release
Potential first-in-class, selective nociceptin receptor (NOP) agonist that aims to provide safe, effective treatment for moderate to severe acute pain. Following successful Phase I results earlier this year demonstrating an excellent safety profile, the program has now progressed to Phase II. The randomized, double-blind, double-dummy, placebo- and active controlled, 2-part Phase II trial will evaluate the safety, tolerability and efficacy of this novel NOP agonist in patients post bunionectomy surgery. Grünenthal anticipates reporting results in early 2028.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom